BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells.

导出 LinkOut

翻译打印收藏纠错

第一作者： Chisato,Inoue

第一单位： College of Life and Health Sciences, Chubu University, Matsumoto-cho 1200, Kasugai 487-8501, Japan.

作者： Chisato,Inoue ^[1] ; Sayaka,Sobue ^[1] ; Yuka,Aoyama ^[1] ; Naoki,Mizutani ^[1] ; Yoshiyuki,Kawamoto ^[1] ; Yuji,Nishizawa ^[1] ; Masatoshi,Ichihara ^[1] ; Akihiro,Abe ^[2] ; Fumihiko,Hayakawa ^[2] ; Motoshi,Suzuki ^[3] ; Yoshinori,Nozawa ^[4] ; Takashi,Murate ^[1]

作者单位： College of Life and Health Sciences, Chubu University, Matsumoto-cho 1200, Kasugai 487-8501, Japan. ^[1] Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya 461-8560, Japan. ^[2] Division of Molecular Oncology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan. ^[3] Tokai Gakuin University, Kakamigahara 504-8511, Japan. ^[4]

关键词 ABL, Abelson kinase ALL, acute lymphoblastic leukemia BCL2 inhibitor BCR, break clustering region CML, chronic myeloid leukemia DST, dasatinib IMT, imatinib Imatinib-resistance JNK inhibitor NRT, nirotinib Ph+ ALL Ph+, Philadelphia chromosome positive Synergistic action TKI, tyrosine kinase inhibitor

DOI 10.1016/j.bbrep.2018.07.001

PMID 30073206

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览9

Biochemistry and biophysics reports

2018年15卷

69-75页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells.

Biochemistry and biophysics reports

相似文献

Biochemistry and biophysics reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells.

Biochemistry and biophysics reports

相似文献

Biochemistry and biophysics reports

相关期刊

检索历史清除